Yuji Miyamoto1, Eiji Oki2, Yasunori Emi3, Shoji Tokunaga4, Mototsugu Shimokawa5, Yutaka Ogata6, Yoshito Akagi7, Yasuo Sakamoto1, Takaho Tanaka8, Hiroshi Saeki2, Yoshihiko Maehara2, Hideo Baba9. 1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. 2. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 3. Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan. 4. Medical Information Center, Kyushu University Hospital, Fukuoka, Japan. 5. Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. 6. Department of Surgery, Kurume University Medical Center, Kurume, Japan. 7. Department of Surgery, Kurume University School of Medicine, Kurume, Japan. 8. Department of Surgery, Social Insurance Tagawa Hospital, Tagawa, Japan. 9. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan hdobaba@kumamoto-u.ac.jp.
Abstract
AIM: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. RESULTS: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). CONCLUSION: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC. Copyright
AIM: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. RESULTS: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). CONCLUSION: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC. Copyright
Authors: Hans-Ulrich Kauczor; Cornelia M Ulrich; Caroline Himbert; Jennifer Ose; Johanna Nattenmüller; Christy A Warby; Andreana N Holowatyj; Jürgen Böhm; Tengda Lin; Mariam Haffa; Biljana Gigic; Sheetal Hardikar; Dominique Scherer; Lin Zielske; Petra Schrotz-King; Torsten Kölsch; Erin M Siegel; David Shibata; Alexis Ulrich; Martin Schneider; Stephen D Hursting Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514
Authors: Megan E Buechel; Danielle Enserro; Robert A Burger; Mark F Brady; Katrina Wade; Angeles Alvarez Secord; Andrew B Nixon; Seyedehnafiseh Mirniaharikandehei; Hong Liu; Bin Zheng; David M O'Malley; Heidi Gray; Krishnansu S Tewari; Robert S Mannel; Michael J Birrer; Kathleen N Moore Journal: Gynecol Oncol Date: 2021-03-10 Impact factor: 5.482